



For further information:
Investor Relations (Tel: +34 91 244 44 22)
Marta Campos Martínez mcampos@rovi.es

ROVI announces the upcoming marketing of Orvatez® in Spain

Madrid, 12th of June 2015 – Laboratorios Farmacéuticos Rovi, S.A. (ROVI or the Company”) announces today that has signed an agreement with Merck Sharp & Dohme S.A. (MSD) to market in Spain Orvatez®, a drug that combines two active principle ingredients, ezetimibe and atorvastatin, which act by inhibiting the two sources of origin of cholesterol. It is indicated for adults patients with primary hypercholesterolemia (increased levels of cholesterol in blood) or mixed (high levels in blood of cholesterol and triglycerides) when the use of product combination is considered adequate. Orvatez® can be used in patients not controlled adequately with a single statine or in patients already treated with statine and ezetimibe. Orvatez® will be marketed in Spain, under a co-marketing regimen with Atozet® which is already being marketed by MSD.

Orvatez® is part of the first of the five marketing agreements that MSD granted ROVI on their products, under the strategic pharmaceutical agreement to market and to manufacture reached on the 23rd of July, 2009, and notified on the next day, on July the 24th 2009, to the National Stock Market Commission as Relevant Fact, with number 111,707.

With Orvatez®, ROVI expands its product´s portfolio and strengthen its commitment to the area of hypercholesterolemia in which is currently offering two products of MSD, Absorcol® and Vytorin®, as alternative therapies for cholesterol problems.

Hypercholesterolemia is the presence of increased levels of cholesterol in the blood. It is one of main cardiovascular risk factors. The cardiovascular diseases such as angina pectoris, myocardial infarction, cerebrovascular diseases, and the peripheral vascular disease are one of the main causes of death in our country. In Spain, the CODIMET study evidenced that just 12% of the patients with coronary heart disease or equivalent risk have their LDL cholesterol levels controlled¹.

Juan López-Belmonte Encina, Chief Executive Officer of ROVI, commented: “we are very enthusiastic with the potential of Orvatez®. This drug offers coronary patients an easy therapeutic option, in a single tablet, to reach LDL cholesterol objectives of each patient, reducing this important cardiovascular risk factor, and is in line with the ongoing objective of ROVI to improve quality of life of patients. Likewise, the marketing of this product comes to consolidate our relationship with MSD that will allow, predictably, launching other licenses of MSD during the next years”.

About ROVI

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI’s portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin. ROVI’s research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISM® technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging

¹ Pérez de Isla L, Saltijeral Cerezo A, Vitale G, Gonzalez Timón B, Torres Do Rego A, Álvarez-Sala LA. Prevalencia del colesterol LDL inadecuado en pacientes con enfermedad coronaria y/o diabetes mellitus tipo 2. Rev Clin Esp 2012; 212:475-81

capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction. Additional information about ROVI is available on the company's website: www.rovi.es